Avai Bio (AVAI) Cash from Investing Activities (2018 - 2023)

Avai Bio has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$149000.0 for Q2 2023.

• Cash from Investing Activities for Q2 2023 came in at -$149000.0, down 544.64% year-over-year; the trailing twelve-month figure through Mar 2024 was -$149000.0 (down 344.64% YoY), and the FY2024 annual result was -$149000.0, down 344.64% from the prior year.
• Cash from Investing Activities came in at -$149000.0 for Q2 2023 at Avai Bio, down from -$67020.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $33510.0 in Q2 2022 to a low of -$149000.0 in Q2 2023.
• The 5-year median for Cash from Investing Activities is -$33285.0 (2021), against an average of -$39151.6.
• Peak annual rise in Cash from Investing Activities reached 7897.61% in 2022, while the deepest fall reached 7756.98% in 2022.
• Avai Bio's Cash from Investing Activities stood at -$75000.0 in 2019, then jumped by 98.38% to -$1216.0 in 2020, then tumbled by 2637.25% to -$33285.0 in 2021, then sank by 101.35% to -$67020.0 in 2022, then sank by 122.32% to -$149000.0 in 2023.
• The last three Cash from Investing Activities figures came in at -$149000.0 (Q2 2023), -$67020.0 (Q3 2022), and $33510.0 (Q2 2022), per Business Quant data.